reViral receives over US$1Mn in funding
4 December 2014 | By reViral
Second tranche of Seeding Drug Discovery award from Wellcome Trust Innovations...
List view / Grid view
News
Alizé Pharma acquires exclusive worldwide rights on a new peptide to tackle bone diseases
3 December 2014 | By Alizé Pharma III SAS
Dr. David Clemmons, co-inventor of the technology and a highly reputable key opinion leader in endocrinology and metabolism, will collaborate on the drug optimization and development programs...
Evotec and Sanofi discuss major multi-component strategic collaboration
3 December 2014 | By Evotec
Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.
BioVersys and Enamine announce extension of drug discovery collaboration to address multidrug-resistant bacterial infections
2 December 2014 | By BioVersys and Enamine
Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year...
MRC Technology and Shandong International Biotechnology Park (China) to cooperate in new drug for Alzheimer’s
2 December 2014 | By MRC Technology
MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of a new Alzheimer’s drug...
World’s first artificial enzymes created using synthetic biology
2 December 2014 | By The Medical Research Council
Medical Research Council scientists have created the world’s first enzymes made from artificial genetic material...
International College of Neuropsychopharmacology (CINP) calls on governments to reverse ‘disturbing’ trend of lack of new drugs for the 10% of the global population affected by brain diseases
2 December 2014 | By The International College of Neuropsychopharmacology
The International College of Neuropsychopharmacology (CINP) has published a paper in Nature Reviews Drug Discovery on how global governments must act to address the dearth of new drugs for central nervous system (CNS) diseases...
ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV
1 December 2014 | By ABIVAX
ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.,,
LaVision BioTec reports on the award-winning scientist Peter Friedl and his work imaging cancer growth
25 November 2014 | By LaVison BioTec
LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Dr Peter Friedl and his imaging of cancer growth using intravital microscopy...
Understanding bacterial toxins target human cells will help develop new drugs
25 November 2014 | By The Lead South Australia
New drugs and treatment strategies will be developed from research that provides a new understanding of how bacterial toxins target human cells...
Bristol-Myers Squibb and Five Prime Therapeutics to evaluate combination of Opdivo (nivolumab) and FPA008 in six tumor types
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...
MRC Technology and Yabao Pharmaceuticals announce exclusive partnership in China to develop novel therapeutics for Parkinson’s disease
24 November 2014 | By MRC Technology / Yabao Pharmaceuticals
MRC Technology and Yabao Pharmaceutical Co, Inc. today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease...
Professor Paul Workman pledges three-pronged attack on cancer evolution and drug resistance
21 November 2014 | By The Institute of Cancer Research
Professor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, London
Scientists discover bacteria’s clever defence mechanism
19 November 2014 | By Diamond
Structure of EzrA protein could help identify new antibiotic targets...
BerGenBio receives orphan-drug designation from FDA for BGB324 in the treatment of acute myeloid leukaemia
19 November 2014 | By BerGenBio
BerGenBio AS, an oncology biopharmaceutical company, announces that the US Food and Drug Administration (FDA) has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML)...
